BDSX Biodesix

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference

BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025.

Canaccord Genuity 45th Annual Growth Conference

Fireside Chat Date: Tuesday, August 12, 2025

Fireside Chat Time: 4:30 PM ET

Location: Boston, MA

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at .

About Biodesix

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit .

Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.

Contacts:

Media:

Natalie St. Denis



1-720-925-9285

Investors:

Chris Brinzey



1-339-970-2843



EN
05/08/2025

Underlying

BDSXBiodesix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biodesix

 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Hig...

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "B...

19h / 27m 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Participate in Upcoming Investor Conferences

Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team will participate in two upcoming investor conferences: TD Cowen's 46th Annual Health Care ConferenceFireside Chat Date: Tuesday, March 3, 2026Fireside Chat Time: 2:30 PM ETLocation: Boston, MA Barclays 28th Annual Global Healthcare ConferenceFireside Chat Date: Wednesday, March 11, 2026Fireside Chat Time: 12:00 PM ETLocation: Miami, FL The fireside chats will be...

February 24, 2026 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results...

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the close of trading on Thursday, February 26. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this . Anal...

February 12, 2026 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Resul...

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX) (the company), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). The financial results included in this release pertaining t...

January 12, 2026 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

Biodesix to Present New Data at Two Major Upcoming Scientific Meetings Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagn...

December 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch